NCT00659360 · OUTCOME

Overall Survival

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma · Source last updated 2018-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: Up to 5 years

What was measured

Median was estimated. The Kaplan-Meier method will be used to estimate overall survival estimates.

Groups in this outcome

Arm I

Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity. saracatinib: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I	17

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Arm I	16.1	Not reported	3.8	17.9	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
3.8
upper Limit
17.9
value
16.1

denoms

counts
group Id
OG000
value
17
units
Participants

description

Median was estimated. The Kaplan-Meier method will be used to estimate overall survival estimates.

dispersion Type

95% Confidence Interval

groups

description
Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity. saracatinib: Given orally
id
OG000
title
Arm I

param Type

MEDIAN

reporting Status

POSTED

time Frame

Up to 5 years

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice